47th week of 2010 patent applcation highlights part 35 |
Patent application number | Title | Published |
20100297098 | Purification of Factor XIII Polypeptides from Biological Materials - The invention relates to a method for purifying a factor XIII polypeptide from a biological material, the method comprising subjecting the material to sequential chromatography on an anion-exchange matrix and a hydrophobic interaction matrix. | 2010-11-25 |
20100297099 | Airway Administration of Activated Protein C in Inflammatory Conditions Affecting the Respiratory Tract - The present invention provides methods for the local treatment of acute and chronic extravascular pulmonary fibrin deposition and/or reducing unwanted effects associated with systemic administration of anticoagulants to a subject via airway administration to the subject by intratracheal, intrabronchial or intraalveolar routes of human activated protein C or biologically active derivatives thereof. | 2010-11-25 |
20100297100 | Composition for Treating Retinopathy or Glaucoma Comprising Thrombin Derived Peptides - Disclosed is a composition for treating retinopathy comprising thrombin derived peptide as an effective component. | 2010-11-25 |
20100297101 | Integrin alpha. II .B.beta.3 Specific Antibodies and Peptides - The present invention provides integrin α | 2010-11-25 |
20100297102 | SEROTONIN 5-HT3A RECEPTORS IN TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS - Methods are provided for modulating post-natal migration of neurons. Activation of the 5-HT3A receptor increases migration, while pharmacological blockade of the 5-HT3A receptor disrupts neuroblast migration into the cortex and hippocampus. These neuroblasts mature into GABAergic interneurons, and thus are relevant to conditions associated with disturbances in 5-HT levels and GABAergic inhibition. | 2010-11-25 |
20100297103 | ANTIBODY HAVING ENHANCED ADCC ACTIVITY AND METHOD FOR PRODUCTION THEREOF - Disclosed is an antibody having an enhanced ADCC activity. Also disclosed is a method for producing the antibody. It was attempted to advance the technique of the amino acid mutation in an Fc region established by researchers of Genentech Inc. or the like, and a study was made on whether or not the ADCC activity can be enhanced by the mutation of an amino acid residue in an Fc region into cysteine (Cys) which may cause a drastic structural change that cannot be drawn by a computational search. As a consequence, a chemeric antibody is provided which has the mutation of an amino acid residue at least one position selected from the group consisting of 286th, 287th, 288th, 289th, 290th, 291st, 292nd, 294th, 298th, 301st, 302nd, 303rd, 305th, 306th, 307th, 308th and 309th positions into a Cys residue in an H-chain constant region. | 2010-11-25 |
20100297104 | DENDRITIC MACROMOLECULE AND A PROCESS THEREOF - The present invention is in relation to a dendritic molecule having symmetrically sited branches having four or more generations of dendrimers wherein the branch points are tertiary amines linked together with oxygen atom of ether and the heteroatoms are separated by a substituted or non-substituted linear three methylene linker. In addition the invention also provides a process to prepare such dendritic macromolecules. | 2010-11-25 |
20100297105 | ADMINISTERING ANTISENSE OLIGONUCLEOTIDES COMPLEMENTARY TO HUMAN APOLIPOPROTEIN B - Methods for long-term lowering of lipid levels in human subjects and for the treatment of conditions associated with elevated LDL-cholesterol and elevated ApoB are provided. | 2010-11-25 |
20100297106 | Pharmaceutical Formulations - A stable pharmaceutical formulation is provided that comprises a biologically active protein and an excipient selected from carnitine, creatine or creatinine. | 2010-11-25 |
20100297107 | HMGB1 PROTEIN INHIBITORS AND/OR ANTAGONISTS FOR THE TREATMENT OF VASCULAR DISEASES - A method of treating vascular diseases by administering an antagonist molecule that inhibits the interaction between a protein of the HMG box family and a receptor for the protein of the HMG box family. | 2010-11-25 |
20100297108 | METHOD OF PROVIDING PATIENT SPECIFIC IMMUNE RESPONSE IN AMYLOIDOSES AND PROTEIN AGGREGATION DISORDERS - A novel treatment of Alzheimer's disease and other disorders involving protein misfolding or aggregation is provided by enhancing or sustaining an antibody response against predominantly directed against pathological protein aggregates or neo-epitopes present on pathogenic forms of said protein or protein complex. Furthermore, therapeutic methods are also described, wherein ex vivo stimulated antigen-selected peripheral blood lymphocytes are regrafted into the cognate donor. | 2010-11-25 |
20100297109 | METHODS FOR INHIBITING FASCIN - The invention relates to compositions and methods useful for inhibiting fascin. These compositions and methods can be used to inhibit fascin-related diseases. For example, according to the invention inhibition of fascin inhibits metastasis of tumor cells in mammals. | 2010-11-25 |
20100297110 | ANTIBODY SPECIFIC FOR HUMAN IL-4 FOR THE TREATMENT OF CANCER - The present invention relates to the use of an antibody or an antigen-binding fragment thereof with specific binding activity for human interleukin-4 for the prevention and/or treatment of cancer. | 2010-11-25 |
20100297111 | Nanobodies against tumor necrosis factor-alpha - The present invention relates to improved Nanobodies™ against Tumor Necrosis Factor-alpha (TNF-alpha), as well as to polypeptides comprising or essentially consisting of one or more of such Nanobodies. The invention also relates to nucleic acids encoding such Nanobodies and polypeptides; to methods for preparing such Nanobodies and polypeptides; to host cells expressing or capable of expressing such Nanobodies or polypeptides; to compositions comprising such Nanobodies, polypeptides, nucleic acids or host cells; and to uses of such Nanobodies, such polypeptides, such nucleic acids, such host cells or such compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes. | 2010-11-25 |
20100297112 | COMBINATIONS COMPRISING DMXAA FOR THE TREATMENT OF CANCER - The present invention relates to combinations of compounds such as compounds of the xanthenone acetic acid class such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and vascular endothelial growth factor binders, in particular the monoclonal antibody Avastin™ (bevacizumab). More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical formulations containing such combinations. | 2010-11-25 |
20100297113 | QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF - This application describes quinone derivatives which target the redox site of Ape1/Ref1. Also included in the invention are pharmaceutical formulations containing the derivatives and therapeutic uses of the derivatives. | 2010-11-25 |
20100297114 | ANTIGEN PRESENTING CELL TARGETED VACCINES - The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies. | 2010-11-25 |
20100297115 | USE OF TRKB ANTIBODIES FOR THE TREATMENT OF RESPIRATORY DISORDERS - The invention discloses TrkB antibodies for the development of new therapeutics to treat, prevent or ameliorate respiratory disorders. The invention also relates to methods to treat, prevent or ameliorate said conditions and pharmaceutical compositions therefor, as well as to a method to identify compounds with therapeutic usefulness to treat conditions associated with respiratory disorders. | 2010-11-25 |
20100297116 | USES OF A GLYCOPROTEIN VI (GPVI) INHIBITOR - The present invention describes a method for reducing reperfusion injury and/or infarction by using an inhibitor of platelet GPVI. This method may be used to treat patients during or after a heart attack or elective cardiac surgery. | 2010-11-25 |
20100297117 | AQUEOUS FORMULATION OF ERYTHROPOIESIS STIMULATING PROTEIN STABILISED BY ANTIOXIDANTS FOR PARENTERAL ADMINISTRATION - The present invention relates to stable aqueous protein formulations. In particular, disclosed herein are therapeutic protein formulations suitable for parenteral administration having one or more antioxidants. | 2010-11-25 |
20100297118 | Therapeutic Cancer Treatments - Provided are methods for treating non-small cell lung cancer by administering a therapeutically effective amount of a hedgehog inhibitor. | 2010-11-25 |
20100297119 | BONE TARGETED ALKALINE PHOSPHATASE, KITS AND METHODS OF USE THEREOF - A bone targeted alkaline phosphatase comprising a polypeptide having the structure: Z-sALP-Y-spacer-X-W | 2010-11-25 |
20100297120 | APROTININ-LIKE POLYPEPTIDES FOR DELIVERING AGENTS CONJUGATED THERETO TO TISSUES - Based on our identification of a polypeptide (Angiopep-7) that is efficiently transported to cells such as liver, lung, kidney, spleen, and muscle, the invention provides polypeptides, conjugates including the polypeptides, and methods for treating diseases associated with these cell types. Unlike other aprotinin related polypeptides identified herein (including Angiopep-3, Angiopep-4a Angiopep-4b Angiopep-5, and Angiopep-6) which efficiently cross the blood-brain barrier (BBB), Angiopep-7 is not efficiently transported across the BBB. | 2010-11-25 |
20100297121 | Methods for Treating Pressure Induced Optic Neuropathy, Preventing Neuronal Degeneration and Promoting Neuronal Cell Survival Via Administration of LINGO-1 Antagonists and TrkB Agonists - This invention relates to methods for promoting neuronal survival and regeneration using LINGO-1 antagonists and TrkB agonists. Additionally, the invention relates to methods for treating pressure induced optic neuropathies using LINGO-1 antagonists. The invention also relates generally to methods for increasing TrkB activity and inhibiting JNK pathway signaling using a LINGO-1 antagonist. | 2010-11-25 |
20100297122 | FORMULATIONS FOR TACI-IMMUNOGLOBULIN FUSION PROTEINS - The invention relates to formulations of TACI-Immunoglobulin fusion proteins. | 2010-11-25 |
20100297123 | COMBINATION THERAPY TO INHIBIT T CELL EFFECTOR FUNCTION - Methods and compositions are provided for inhibiting the responsiveness of CD4 | 2010-11-25 |
20100297124 | INDUCED INTERNALIZATION OF SURFACE RECEPTORS - Disclosed is a hetero-bifunctional ligand for use in inducing internalization of a target receptor. The hetero-bifunctional ligand includes a target receptor-binding agent that specifically binds the target receptor linked to an internalizing receptor-binding agent that specifically binds to an internalizing receptor, where the two binding agents are non-identical. Also disclosed is a method of inducing the internalization of a target receptor on a cell. The method includes contacting a cell with a hetero-bifunctional ligand, where binding of the hetero-bifunctional ligand induces internalization of a target receptor of the cell. Also disclosed a method of treating a disease or condition associated with a target receptor using the disclosed hetero-bifunctional ligand and pharmaceutical compositions including a hetero-bifunctional ligand. | 2010-11-25 |
20100297125 | METHODS OF TREATING PAIN USING ANTAGONISTS OF IL-31, IL-31RA AND/OR OSMRB - Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated. | 2010-11-25 |
20100297126 | Monoclonal Antibodies Specific to Hemagglutinin from Influenza Virus H5-Subtype and Uses Thereof - Monoclonal antibodies and related binding proteins that are specific for conformational epitopes of avian influenza virus K5 subtype hemagglutinin glycoprotein are provided. The antibodies can be used for the detection and treatment of H5 subtype AIV in specimens. | 2010-11-25 |
20100297127 | USE OF IL-27 ANTAGONISTS TO TREAT LUPUS - This invention relates to methods of treating the autoimmune disorder lupus with IL-27 antagonists, as well as articles of manufacture comprising IL-27 antagonists. The invention also relates to methods and kits for identifying patients that are likely to respond to an IL-27 antagonist treatment. | 2010-11-25 |
20100297128 | GAMMA SECRETASE MODULATORS - This invention provides novel compounds that are modulators of gamma secretase. The compounds have the formula [Chemical formula should be inserted here as it appears on abstract in electronic form.] Also disclosed are methods of modulating gamma secretase activity and methods of treating Alzheimer's disease using the compounds of formula (I). | 2010-11-25 |
20100297129 | METHOD FOR EXTENDING PREGNANCY IN PATIENTS EXHIBITING AT LEAST ONE SYMPTOM OF PREECLAMPSIA AND ECLAMPSIA - A composition is provided to prevent, limit the effects of, delay the onset of, or treat one or more of the causes, symptoms or complications of gestational hypertension, preeclampsia, eclampsia and/or intrauterine growth restriction. The composition comprises a therapeutically effective amount of an antibody that reacts immunologically with or binds digoxin and has a high dose of digoxin binding capacity as the active ingredient. There is also provided a method of preventing, limiting the effects of, delaying the onset of, or treating a cause, symptom or complication of gestational hypertension, preeclampsia, eclampsia or intrauterine growth restriction, comprising the step of administering to a mammal a composition comprising a therapeutically effective amount of an antibody that reacts immunologically with or binds digoxin and has a high dose of digoxin binding capacity. | 2010-11-25 |
20100297130 | PROTECTIVE ANTI-GLUCAN ANTIBODIES WITH PREFERENCE FOR BETA-1,3-GLUCANS - Anti-β-1,3-glucan antibodies have been found to be protective against systemic fungal infection with | 2010-11-25 |
20100297131 | BINDING DOMAIN OF PLASMODIUM RETICULOCYTE BINDING PROTEINS - The present invention provides isolated polynucleotides, polypeptides, antibodies and/or vaccines for the prevention and/or treatment of malaria caused by | 2010-11-25 |
20100297132 | Monoclonal antibody - The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of β-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD). | 2010-11-25 |
20100297133 | Immunogenic Polypeptides and Monoclonal Antibodies - Provided herein are compositions and methods for eliciting an immune response against | 2010-11-25 |
20100297134 | HUMANISED ANTIBODIES WITH ANTI-TUMOUR ACTIVITY - The present invention provides humanised antibodies and binding domains thereof with anti-tumour activity. In particular the humanised antibodies have specific binding to and direct killing of human colon tumour cells and display potent immune-mediated cytotoxic activity against human colon cancer cells in vitro using antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) assays and in vivo using mouse tumour models. | 2010-11-25 |
20100297135 | EPITOPE FOR NEUTRALIZING ANTIBODIES - Provided herein are immunogenic peptides of GM-CSF comprising an amino acid sequence set forth in any one of SEQ ID NOs:2 to 6, or a portion thereof, and compounds and molecules that specifically interact with or bind to a region of GM-CSF located between, or corresponding to a region located between, about residues 89 and 117 of the human GM-CSF polypeptide sequence as set forth in SEQ NO:1. | 2010-11-25 |
20100297136 | Gastric and Prostate Cancer Associated Antigens - The invention relates to an antigen associated with cancers such as prostate and gastric cancers, known as T21. Nucleic acid sequences and polypeptide sequences encoding the antigen are provided, as are uses of such sequences. | 2010-11-25 |
20100297137 | Hematopoietic Lineage Cell Specific Protein (HS1) as a Marker for Lymphoid Malignancy - Use of a phosphorylated form of hematopoietic-lineage-cell-specific-protein-1 (HS1) as a prognostic or diagnostic marker for a Lymphoid Malignancy, a disease in which B cell receptor stimulation is dysregulated or disease characterised by B lymphocyte proliferation. | 2010-11-25 |
20100297138 | HUMAN MONOCLONAL ANTIBODIES TO FUCOSYL-GM1 AND METHODS FOR USING ANTI-FUCOSYL-GM1 - The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Fucosyl-GM1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting Fucosyl-GM1, as well as methods for treating various diseases, including cancer, using anti-Fucosyl-GM1 antibodies. | 2010-11-25 |
20100297139 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES - The present invention is directed to methods of treating proteinuric diseases by the administration of avβ3 integrin inhibitors. | 2010-11-25 |
20100297140 | USES OF ANTIBODIES - The present invention provides a method of preparing an antibody-containing milk or egg product for use in preventing and/or treating of a non-infectious medical condition. The invention also provides non-systemic modes of administering pharmaceutical compositions including the antibody-containing milk or egg products, including to the GI tract. | 2010-11-25 |
20100297141 | ANTI-ADHESIN BASED PASSIVE IMMUNOPROPHLACTIC - The invention relates to an immunogenic composition and method of the immunogenic composition for the production and administration of a passive immunoprophylactic against enterotoxigenic | 2010-11-25 |
20100297142 | METHODS OF USING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OX- O-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID IN COMBINATION THERAPY - Methods of treating, preventing or managing cancers are disclosed. The methods encompass the administration of SNS-595 in combination with a second active agent. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with cisplatin, carboplatin, gemcitabine or a combination thereof. | 2010-11-25 |
20100297143 | METHODS FOR TREATING PSORIASIS - The invention provides a method of treating psoriasis in a subject by administering to a subject an antibody capable of binding to the p40 subunit of IL-12 and/or IL-23. | 2010-11-25 |
20100297144 | MULTITYPE HPV PEPTIDE COMPOSITIONS AND METHODS FOR TREATMENT OR PREVENTION OF HUMAN PAPILLOMAVIRUS INFECTION - Embodiments of the invention are directed to methods and compositions of multitype HPV polypeptides. | 2010-11-25 |
20100297145 | Apoptosis promoter, cell proliferation inhibitor, prophylactic/therapeutic agent for cancer, screening method for the promoter, inhibitor or agent - Disclosed is an apoptosis promoter, cell proliferation inhibitor, prophylactic/therapeutic agent for cancer or the like which comprises a compound capable of inhibit the expression or function of PCA-1 as an active ingredient. Also disclosed is a method for screening of a compound for use in the promotion of apoptosis, the inhibition of cell proliferation or the prevention/treatment of cancer, which comprises selecting a compound capable of inhibit the expression or function of PCA-1, or the like. | 2010-11-25 |
20100297146 | IMMUNE SYSTEM PROGRAMMING THROUGH B7-DC - Materials and methods related to modulating immune responses (e.g., altering the polarity of immune responses) are provided. | 2010-11-25 |
20100297147 | COMPOSITIONS AND METHODS FOR MODULATING TLR14 ACTIVITY - Methods and compositions for modulating neural cell function using antagonists of TLR14 are disclosed. In particular, methods for treating, preventing and/or diagnosing TLR14-associated neurodegenerative conditions and/or disorders are disclosed. Screening methods for evaluating TLR14 modulators, e.g., agonists and antagonists, are also disclosed. | 2010-11-25 |
20100297148 | CD38 MODULATED CHEMOTAXIS - The present invention relates to methods for modulating the migratory activity of cells expressing CD38 for the treatment of disorders including, but not limited to, inflammation, ischemia, asthma, autoimmune disease, diabetes, arthritis, allergies, infection with pathogenic organisms, such as parasites, and transplant rejection. Such cells include, for example, neutrophils, lymphocytes, eosinophils, macrophages and dentritic cells. The invention further relates to drug screening assays designed to identify compounds that modulate the ADP-ribosyl cyclase activity of CD38 and the use of such. compounds in the treatment of disorders involving CD38 modulated cell migration. Additionally, the invention relates to the isolation and characterization of a CD38 homologue from the parasitic flatworm, | 2010-11-25 |
20100297149 | COMPOSITIONS AND METHODS COMPRISING HISTIDYL-TRNA SYNTHETASE SPLICE VARIANTS HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES - Isolated histidyl-tRNA synthetase splice variant polynucleotides and polypeptides having non-canonical biological activities are provided, as well as compositions and methods related thereto. | 2010-11-25 |
20100297150 | DISEASE TREATMENT VIA ANTIMICROBIAL PEPTIDE INHIBITORS - A method of treating a disease in a subject in need thereof is disclosed. The method comprises providing to the subject a therapeutically effective amount of a compound being capable of decreasing an activity and/or level of an antimicrobial peptide (AMP) and/or AMP-like molecule, thereby treating the disease in the subject in need thereof. | 2010-11-25 |
20100297151 | ANTIBODIES AGAINST HUMAN IL-21 RECEPTOR AND USES THEREFOR - The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21R). The antibodies can act as antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders. | 2010-11-25 |
20100297152 | METHODS OF DIAGNOSIS OF PROSTATE CANCER, COMPOSITIONS AND METHODS OF SCREENING FOR MODULATORS OF PROSTATE CANCER - Described herein are genes whose expression are up-regulated or down-regulated in prostate cancer. Also described are such genes whose expression is further up-regulated or down-regulated in drug-resistant prostate cancer cells. Related methods and compositions that can be used for diagnosis and treatment of prostate cancer are disclosed. Also described herein are methods that can be used to identify modulators of prostate cancer. | 2010-11-25 |
20100297153 | Binding molecules for treatment and detection of cancer - Provided are new tumor-associated antigens, binding molecules that specifically bind to the antigens, nucleic acid molecules encoding the binding molecules, compositions comprising the binding molecules, and methods of identifying or producing the binding molecules. The tumor-associated antigens are expressed on cancer cells and binding molecules capable of specifically binding to the antigens can be used in the diagnosis, prevention and/or treatment of cancer. | 2010-11-25 |
20100297154 | CD40 ligand-enhanced cells and methods of modulating an immune response to an antigen - The invention provides for a method of vaccinating a mammal to a selected antigen, wherein the method comprises administering to a mammal a vaccine composition comprising a CD40 ligand-enhanced cell, wherein the CD40 ligand-enhanced cell comprises a selected antigen and is admixed with an engineered ligand for CD40. | 2010-11-25 |
20100297155 | PHOSPHAZENE HYDROGELS WITH CHEMICAL CORSS-LINK, PREPARATION METHOD THEREOF AND USE THEREOF - A phosphazene-based polymer hydrogel with a chemical cross-linkings formed by radiating ultraviolet (UV) and/or mixing with cross-linking agent and/or enzyme, a method of preparing the same, and a hydrogel forming a chemical cross-linking by radiating ultraviolet and/or mixing with a cross-linking agent and/or an enzyme; where the hydrigel shows a sol-gel behavior and has an excellent solidity by containing the phosphazene-based polymer that is capable of cross-linking at a certain concentration, are provided. | 2010-11-25 |
20100297156 | ANALOGUES OF PHOSPHATIDYLINOSITOL MANNOSIDES - The invention relates to compounds which are immunomodulatory compounds and, in particular, can induce IL-12 secretion. The invention also relates to compositions containing the compounds, precursors, and prodrugs of these compounds, use of these compounds as adjuvants in combination with vaccines, and use of these compounds for treatment of diseases or conditions relating to infection, atopic disorders, or cancer. | 2010-11-25 |
20100297157 | VACCINE THERAPY FOR CHOROIDAL NEOVASCULARIZATION - The present inventors administered a peptide derived from VEGFR-2, which is known as one of the proteins involved in neovascularization, to model mice (A2/Kb transgenic mice) expressing human HLA-A*0201, and tested whether or not the peptide has vaccine effect. As a result, the present inventors successfully discovered that vaccination using this peptide as an antigen is effective for inhibition of choroid neovascularization, and thereby completed the present invention. More specifically, the present invention provides vaccines for treatment and/or prevention of diseases caused by choroid neovascularization (neovascular maculopathy), which contain a VEGFR-2-derived peptide as an active ingredient. | 2010-11-25 |
20100297158 | ANTICANCER VACCINE AND DIAGNOSTIC METHODS AND REAGENTS - The invention provides a method for vaccinating a patient against a malignancy comprising introducing a protein or peptide comprising of all or an immunogenic fragment of a cyclin protein into the patient. The invention further provides a method of identifying tumor antigens. | 2010-11-25 |
20100297159 | THOMSEN-FRIEDENREICH DISACCHARIDE MODIFIED IMMUNOGEN (TFD), PREPARATION PROCEDURE, COMPOSITIONS COMPRISING IT, USES, AND TREATMENT METHODS - Modified Thomsen-Friedenreich disaccharide (TFD) immunogen, preparation procedure, compositions containing it, uses, and treatment methods. More specifically, the present invention refers to a immunogen obtained by modifying TFD, and comprising the general formula D-TFD-Lys(n)-C, wherein D is a hydrophobic terminal residue, TFD is disaccharide Galβ3GalNAcα; Lys(n) is a lysine connector, and n is an integer between 1 and 5, and C is a carrier. In a preferred embodiment, the modified invention immunogen comprises the general formula BzlαTFD-Lys5-KLHs, wherein Bzl is benzyl, TFD is disaccharide Galβ3GalNAcα; Lys5 is penta-lysine, and KLHs is succinilated Keyhole limpets hemocyanin. | 2010-11-25 |
20100297160 | High Molecular Weight Amyloid Beta As a Carrier for the Oral Delivery of Vaccine Antigens - Compositions and methods are provided for stabilizing polypeptide antigens such as amyloid-beta (Aβ) to produce vaccines for oral delivery. One embodiment provides an immunogenic polypeptide complex of Aβ | 2010-11-25 |
20100297161 | IMMUNOPROTECTIVE INFLUENZA ANTIGEN AND ITS USE IN VACCINATION - The present invention relates to an influenza antigen, comprising a fusion product of at least the extracellular part of a conserved influenza membrane protein or a functional fragment thereof and a presenting carrier, which may be a presenting (poly)peptide or a non-peptidic structure, such as glycans, peptide mimetics, synthetic polymers. The invention further relates to a vaccine against influenza, comprising at least an antigen of the invention, optionally in the presence of one or more excipients. The invention also relates to use of the antigen, a method for preparing the antigen and acceptor cells expressing the antigen. | 2010-11-25 |
20100297162 | S. EPIDERMIDIS ANTIGENS - Hyperimmune serum reactive antigens and fragments thereof are disclosed. In addition, methods for isolating such antigens and specific uses thereof, including the treatment of | 2010-11-25 |
20100297163 | RECOMBINANT MALARIA VACCINE - The present invention refers to a recombinant malaria vaccine and a method for its manufacture. | 2010-11-25 |
20100297164 | Chlamydial Antigens - The invention is in the field of immunology and vaccinology. In particular, it relates to antigens derived from | 2010-11-25 |
20100297165 | IMMUNOSTIMULATORY COMBINATIONS OF TLR LIGANDS AND METHODS OF USE - The present invention provides immunostimulatory combinations of TLR ligands and therapeutic and/or prophylactic methods that include administering an immunostimulatory combination to a subject. In general, the immunostimulatory combinations described herein can provide an increased immune response compared to other immunostimulatory combinations and/or compositions. | 2010-11-25 |
20100297166 | Meningococcal Oligosaccharide Linked Polysaccharides and Diptheria Protein Conjucate Vaccine for All Ages - Methods for producing quadrivalent meningococcal meningitis polysaccharide and conjugate vaccines for serotypes A, C, Y and W-135 disclosed. | 2010-11-25 |
20100297167 | Method for the Production of Recombinant Virus, DNA Constructs, Recombinant Virus and Vaccine Compositions - The purpose of the present invention is the production of recombinant virus through the cloning and expression of sequences of coding nucleotides of the whole or part of heterolog proteins, through the following method: (a) modification of the heterolog nucleotides sequences in such way they when cloned and expressed in the vector virus, they present in the 5′ region, nucleotides present in the 5′ edge of the gene NS1 of this vector virus or of other virus or equivalent functional sequences, and in its 3′ region, the correspondent genome region in the whole or part of the spheres of the steam and anchor of the protein E of this vector virus or equivalent functional sequences, and not compromising the structure and the replication of the mention vector virus; (b) insertion of the modified heterolog sequences in (a) in the intergene region at the structural protein E level and of on structural NS1 vector virus; (c) obtention of the non pathogenic recombinant virus and owner of the immunologic properties, having the heterolog sequences integrated in the viral genome according to the insertion described in (b) and, like that, expressing the heterolog antigene in such way that it can induce an appropriate immune response. The present invention is also addressed to vaccine compositions to immune against the Flavivirus and/or other pathogens. | 2010-11-25 |
20100297168 | LENTIVIRAL GENE TRANSFER VECTORS AND THEIR MEDICINAL APPLICATIONS - The present invention relates to the design of gene transfer vectors and especially provides lentiviral gene transfer vectors suitable for either a unique administration or, for iterative administration in a host, and to their medicinal application (such as vaccination against Immunodeficiency Virus, especially suitable in human hosts). Gene transfer vectors are either integrative or non-integrative (NI) vectors, dependently upon the purpose of their use. The invention relates to the use of gene transfer vectors for unique or for multiple in vivo administration into a host in need thereof. The field of application of the present application concerns in particular animal treatment or treatment of human being (e.g. prophylactic or therapeutic or symptomatic or curative treatment), gene therapy or vaccination in vivo. These vectors may be used to elicit an immune response to prevent or to treat a pathogenic state, including virus infections (for example treatment or prevention against Immunodeficiency Virus and especially against AIDS), parasite and bacterial infections or cancers, and preferably to elicit a protective, long-lasting immune response. | 2010-11-25 |
20100297169 | Novel Neutralizing Immunogen (NIMIV) of Rhinovirus and its Use for Vaccine Applications - The invention relates to methods and compositions for preventing or treating human rhinovirus infection. | 2010-11-25 |
20100297170 | VACCINES - The invention refers an improved vaccine against infections with pathogens, especially viral pathogens, comprising an antigen, a peptide of the formula R | 2010-11-25 |
20100297171 | DEVELOPMENT OF A PREVENTIVE VACCINE FOR FILOVIRUS INFECTION IN PRIMATES - The present invention relates generally to viral vaccines and, more specifically, to filovirus vaccines and methods of eliciting an immune response against a filovirus or disease caused by infection with filovirus. | 2010-11-25 |
20100297172 | REPLICATION-DEFECTIVE ARENAVIRUS VECTORS - The invention relates to an infectious arenavirus particle that is engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but unable to produce further infectious progeny particles in normal, not genetically engineered cells. One or more of the four arenavirus open reading frames glycoprotein (GP), nucleoprotein (NP), matrix protein Z and RNA-dependent RNA polymerase L are removed or mutated to prevent replication in normal cells but still allowing gene expression in arenavirus vector-infected cells, and foreign genes coding for an antigen or other protein of interest or nucleic acids modulating host gene expression are expressed under control of the arenavirus promoters, internal ribosome entry sites or under control of regulatory elements that can be read by the viral RNA-dependent RNA polymerase, cellular RNA polymerase I, RNA polymerase II or RNA polymerase III. The modified arenaviruses are useful as vaccines and therapeutic agents for a variety of diseases. | 2010-11-25 |
20100297173 | PROPHYLACTIC AND THERAPEUTIC IMMUNIZATION AGAINST PROTOZOAN INFECTION AND DISEASE - Polypeptide and polynucleotide vaccines effective to treat or prevent infection of a mammal, such as a dog, a cat, or a human, by a protozoan. Methods of treatment and prevention are also provided, including therapeutic administration of the vaccine to an infected mammal to prevent progression of infection to a chronic debilitating disease state. Preferred embodiments of the polynucleotide vaccine contain nucleotide coding regions that encode polypeptides that are surface-associated or secreted by | 2010-11-25 |
20100297174 | INFLUENZA VIRUS VACCINES AND USES THEREOF - Provided herein are influenza hemagglutinin stem domain polypeptides, compositions comprising the same, vaccines comprising the same and methods of their use. | 2010-11-25 |
20100297175 | Mutations in a toll-like receptor motif in the NS4B of classical swine fever virus strain brescia influences virulence in swine - NS4B is one of the non-structural proteins of classical swine fever virus. By using functional genetics, we have discovered, in the predicted amino acid sequence of NS4B of CSFV strain Brescia, a motif that resembles those found in the toll-like receptor (TLR) proteins, a group of host cell proteins involved in the development of anti-viral mechanisms. We have located the TLR motif in two groups of amino acid triplets at amino acid positions 2531-3 (residues IYK) and 2566-8 (residues VGI) of the CSFV NS4B glycoprotein. We have constructed a recombinant CSFV (derived from an infectious clone containing the genetic information of the highly virulent strain Brescia) containing amino acid substitutions in the three amino acid residues at positions 2566, 2567 and 2568, where the VGI triplet has been replaced by an AAA triplet inside the NS4B glycoprotein. The obtained virus, named NS4B-VGIv, was completely attenuated in swine, showing a limited ability in spreading during the infection in vivo. Although attenuated, NS4B-VGIv efficiently protected swine from challenge with virulent BICv at 3 and 28 days post-infection. | 2010-11-25 |
20100297176 | Polyinosinic Acid - Polycytidylic Acid - Based Adjuvant - The present invention provides a polynucleotide adjuvant composition and methods of use in eliciting an immune response. The present invention also provides an immunogenic composition comprising the polynucleotide adjuvant composition together with an antigen (e.g., as in a vaccine). The adjuvant compositions of the invention have particular physical properties (e.g., molecular weight, concentration, and pH) which address the need for a safe adjuvant for eliciting an enhanced immune response. The present invention further contemplates methods of use of such adjuvant compositions, particularly in eliciting an immune response to an antigenic compound. | 2010-11-25 |
20100297177 | MUTATED PARVOVIRUS STRUCTURAL PROTEINS AS VACCINES - The present invention is related to a method for identifying a parvovirus mutated structural protein capable of specifically binding to a binder for an antigen, a parvovirus mutated structural protein which comprises at least one B-cell epitope heterologous to the parvovirus, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a virus or cell comprising the protein, a method of preparing the protein, a medicament comprising the protein, nucleic acid or multimeric structure and its use. | 2010-11-25 |
20100297178 | NOVEL GENES AND PROTEINS OF BRACHYSPIRA HYODYSENTERIAE AND USE OF SAME FOR DIAGNOSIS AND THERAPY - Novel polynucleotide and amino acids of | 2010-11-25 |
20100297179 | Immunology Treatment for Biofilms - The invention provides a composition for use in raising an immune response to | 2010-11-25 |
20100297180 | BOTULINUM NEUROTOXIN VACCINE - The invention provides compositions comprising an antigenic botulinum neurotoxin serotype E (BoNT/E) peptide, wherein the peptide has improved solubility and thus improved ability to stimulate an immune response against BoNT/E holotoxin. The composition may be used as part of a multivalent vaccine regimen via coordinated use with non-serotype E BoNT peptides, such as one or more BoNT/A and/or BoNT/B peptides. It further provides processes for manufacturing said BoNT/E peptide. It also provides methods of stimulating an immune response in a mammal, comprising administering to the mammal an effective amount of a BoNT/E and optionally one or more non-serotype E BoNT peptides such as one or more BoNT/A and/or BoNT/B peptides. | 2010-11-25 |
20100297181 | AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ - The invention provides methods for treating epilepsy, mental disorders and/or deficits in sensory organ by administering to patients therapeutically effective amounts of AMPA receptor antagonists in combination with one or more other active ingredients useful for treating epilepsy, mental disorders and/or deficits in sensory organ. The invention also provides pharmaceutical combinations, kits, and pharmaceutical compositions comprising therapeutically effective amounts of AMPA receptor antagonists, and optionally, one or more other active ingredients that are useful for treating epilepsy, mental disorders and/or deficits in sensory organ. | 2010-11-25 |
20100297182 | Injectable Amino-acid Composition - An injectable amino-acid composition acts naturally to fuel collagen synthesis, which retards aging and helps to clear cellular decay while accelerating the cell division that promotes healthy, younger looking skin. The amino-acid composition includes carnosine. The composition is injected into the dermis of patients. The composition can be used in conjunction with botulinum toxin and fillers to enhance their effectiveness and extend their usefulness. | 2010-11-25 |
20100297183 | IMMUNOGENIC STREPTOCOCCUS PROTEINS - The invention provides means and methods for identifying a | 2010-11-25 |
20100297184 | Vaccines - The invention provides | 2010-11-25 |
20100297185 | MYCOBACTERIAL MUTANTS AFFECTING HOST APOPTOSIS - Provided are recombinant mycobacteria having a mutation in an nlaA gene or in a nuoG gene. Also provided are isolated and purified nlaA proteins and nuoG proteins from a | 2010-11-25 |
20100297186 | MULTICOMPONENT OR MONOCOMPONENT VACCINE TO BE USED AGAINST CHAGAS DISEASE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PROCEDURE FOR THE OBTENTION OF IMMUNOGEN OF SAID VACCINES, AND NUCLEIC ACID USED IN SAID PROCEDURE - A vaccine against the Chagas disease, capable of stimulating the immune response against the trans-sialidase virulence factor of the | 2010-11-25 |
20100297187 | PEPTIDE SEQUENCES AND COMPOSITIONS - Provided is a polypeptide composition comprising one or more polypeptides, which polypeptides are immunogenic in a vertebrate such that they cause the vertebrate to produce immune system cells capable of recognising at least one epitope from an arthropod saliva protein fraction, wherein the arthropod saliva protein fraction has a mass of 40 kDA or less, and wherein the polypeptides are selected independently from:
| 2010-11-25 |
20100297188 | ALLERGENS AND ALLERGOIDS FROM BEE VENOM - The present invention concerns the preparation of purified allergens and allergoids, both derived from whole bee venom, for the desensitisation (immunotherapy) of subjects affected by a specific allergy. In particular, the present invention concerns a preparation for immunotherapy based on purified bee venom, characterised in that said bee venom is essentially mellitin-free. In addition, the preparation of a monomeric allergoid obtainable through the carbamylation or thiocarbamylation reaction of said mellitin-free bee venom, is described. Said allergoid, being characterised by reduced IgE-binding activity, may be a safer and more effective candidate for specific immunotherapy. | 2010-11-25 |
20100297189 | ALLOGENEIC TUMOR THERAPEUTIC AGENT, A VACCINE USING ALLOGENEIC TUMOR CELLS FOR THE THERAPEUTIC TREATMENT OF TUMOR DISEASES, AND A METHOD FOR THE MAKING OF SUCH A VACCINE, AND TRANSFECTED HUMAN TUMOR CELLS FOR USE AS A VACCINE - Vaccine on the basis of allogeneic tumor cells for the therapeutic treatment of tumor diseases, and a method for the making of such vaccine, furthermore transfected human tumor cells for their use as a vaccine. The abstract of the disclosure is submitted herewith as required by 37 C.F.R. §1.72(b). As stated in 37 C.F.R. §1.72(b): A brief abstract of the technical disclosure in the specification must commence on a separate sheet, preferably following the claims, under the heading “Abstract of the Disclosure.” The purpose of the abstract is to enable the Patent and Trademark Office and the public generally to determine quickly from a cursory inspection the nature and gist of the technical disclosure. The abstract shall not be used for interpreting the scope of the claims. Therefore, any statements made relating to the abstract are not intended to limit the claims in any manner and should not be interpreted as limiting the claims in any manner. | 2010-11-25 |
20100297190 | IDENTIFICATION FEATURES - Methods for providing pharmaceutical compositions and objects with identification regions and identification features which are difficult to detect. Microlithography, nanolithography, and stamping methods are used. The identification features can be positive protrusions or negative indentations with respect to the surface. The identification regions can comprise bar codes and holograms. DPN printing or other lithographies such as electron beam lithography, optical lithography, or nanoimprint lithography can be used to prepare stamps, which are then used to prepare the identification features. Redundant patterns can be formed. The invention is useful for counterfeit prevention. An apparatus for stamping the identification features is also described. | 2010-11-25 |
20100297191 | METHOD FOR MANUFACTURING A CLEANSING AND/OR CARE ARTICLE - The invention relates to the use of a cleansing and/or care composition for impregnating a pile of absorbent supports. | 2010-11-25 |
20100297192 | USE OF MICROPARTICLES FOR VACCINES AND THE RELEASE OF BIOLOGICALLY ACTIVE MOLECULES - The invention relates to microparticles based on a PLGA biodegradable polymer and an alginate polymer which encapsulate immunologically active peptides or proteins. Said microparticles, and the pharmaceutical compositions developed from them and the uses thereof, are applicable to the field of human and animal health as a vaccine and system for releasing biologically active molecules. | 2010-11-25 |
20100297193 | METHODS OF THERAPEUTIC TREATMENT OF EYES - Provided are electrokinetically-altered aqueous fluids (e.g., gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating an irritation, infection or inflammatory eye condition, comprising administering to, by contacting the eye of a subject in need thereof a therapeutically effective amount of an electrokinetically-altered aqueous fluid. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids) and therapeutic compositions for use in treating eye conditions. Certain embodiments relate to cosmetic and/or therapeutic fluids and/or methods of treatment utilizing the fluids to treat a cosmetic and/or therapeutic symptom related to eye conditions and/or diseases. | 2010-11-25 |
20100297194 | FORMULATION FOR ORAL ADMINISTRATION OF APOPTOSIS PROMOTER - An orally deliverable pharmaceutical composition comprises as a sole or first active ingredient a compound of Formula I defined herein or a pharmaceutically acceptable salt thereof, for example ABT-263 free base or ABT-263 bis-HCl salt, dispersed, in a free base equivalent amount of at least about 2.5% by weight of the composition, in a pharmaceutically acceptable carrier; wherein said active ingredient is in solid-state form and/or the composition further comprises, dispersed in the carrier, a pharmaceutically acceptable heavier-chalcogen antioxidant in an amount effective to inhibit oxidation of the active ingredient at a thioether linkage thereof. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer. | 2010-11-25 |
20100297195 | CONTROLLED RELEASE LAMOTRIGINE FORMULATIONS - The present invention relates to controlled release formulations comprising lamotrigine and process for preparation thereof. | 2010-11-25 |
20100297196 | Cytokine modulators using cyclic glycerides of essential polyunsaturated fatty acids - A method of treating a patient in need of therapy for a cytokine dysregulation comprising administering to that patient a therapeutically effective dose of a compound of general formula: (I) wherein R | 2010-11-25 |
20100297197 | Non-fluoride containing dietary supplement toothpaste and methods of using the same - A non-fluoride containing toothpaste enriched with at least one dietary supplement. The non-fluoride containing toothpaste comprising a dentally acceptable oral vehicle containing a sufficient amount of thickening agent to impart a pasty consistency; and at least one dietary supplement wherein a serving size portion of the non-fluoride containing toothpaste contains more than about | 2010-11-25 |